Eric K. Singhi, MD

Thoracic Medical Oncologist, Assistant Professor @MDAndersonNews | Patient education & young-onset lung cancer | 🫁#cancer #lcsm @LungCancerRx | Views my own

[Eric K. Singhi, MD @lungoncdoc]

Our patient-focused publication on young-onset lung cancer is now published in @JAMAOnc.

To every patient told they were ‘too young’ for lung cancer, and to the families who stood beside them, this is for you 🤍. @MDAndersonNews

https://t.co/kT9ZmKOBCe

[Brendon Stiles @BrendonStilesMD]

@jryckman3 @lungoncdoc @OncLive @NarjustFlorezMD @DrEdKim In fact, radiographic assessment & RECIST likely OVERestimate local control after RT.

Look - the intent wasn't to antagonize. Rather it was to open minds to the concept of neoadj for all irrespective of local modality. I showed some great work led by @NitinOhri3 @MontefioreNYC.

[Eric K. Singhi, MD @lungoncdoc]

If you voted for our #BTGLung2026 polls, you’ll want to see the results here!!

@OncLive @NarjustFlorezMD @DrEdKim

[OncLive.com @OncLive]

https://t.co/goIdjSPrRs

[Brendon Stiles @BrendonStilesMD]

Thanks @lungoncdoc for posting! And thanks to @OncLive for bringing such a great collection of experts together to bridge the current gaps in lung cancer care.

[Oncology Brothers @OncBrothers]

Waiting on official @FDAOncology but based on PR, Zidesamtinib now @US_FDA ✅ for previously treated #ROS1 NSCLC, ARROS-1 study:

- RR 44%
- DoR 12mos: 69%
- AEs: Edema, neuropathy, constipation, fatigue and dyspnea. But discontinuation rate was very low.

#OncTwitter #lcsm

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

The slides end. The ideas don’t.

One unforgettable evening with brilliant colleagues, meaningful conversations, and spectacular views.

Thank you, @DrEdKim , for hosting the Bridging the Gaps faculty dinner.

#BTGLung26 @OncLive

[Eric K. Singhi, MD @lungoncdoc]

Very timely review of the evolution of ROS1 directed TKIS happening here at #BTGLung2026

And now, HOT off the press as of THIS MORNING, FDA approval for zidesamtinib in patients who received a prior ROS1 TKI.

@OncLive

[LUNGevity Foundation @LUNGevity]

Dr. Arthi Sridhar wants you to know that clinical trials should be considered at every step in a patient's care, not just as an option after other treatments have been exhausted.Hear more from Dr. Sridhar in the latest podcast episode: https://t.co/P2FccpdrAS

#lcsm #lungcancer

[Eric K. Singhi, MD @lungoncdoc]

Management after neoadjuvant therapy in NSCLC...

What do we know, and what are the gaps?

#BTGLung2026 @OncLive

[Eric K. Singhi, MD @lungoncdoc]

Top 5 questions still shaping the role of RT in oligometastatic NSCLC:

1. Who?
2. When?
3. Where?
4. How much?
5. Which biology?

Quick plug for our @JAMAOnc patient page on LCT in lung cancer. @maraantonoff: https://t.co/4q3x431Jaw

#BTGLung2026 @PercyLeeMD

[Stephen V Liu, MD @StephenVLiu]

Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Hear from Dr. @BrunaPellini as she discusses current and future options for KRAS & HER2 mutant NSCLC!

https://t.co/EGGHrShgD7

[Eric K. Singhi, MD @lungoncdoc]

Oligometastatic NSCLC - what would be your next step in management? @PercyLeeMD @OncLive #BTGLung2026

[Eric K. Singhi, MD @lungoncdoc]

@BrendonStilesMD @OncLive We missed you here!!

[Eric K. Singhi, MD @lungoncdoc]

Borderline resectable NSCLC - the path forward? @BrendonStilesMD

1. Think biology > anatomy.
2. Systemic therapy first.
3. Always reassess resectability.
4. Don't label unresectable too early.
5. Right patient. Right therapy. Right time.

#BTGLung2026

[Eric K. Singhi, MD @lungoncdoc]

CM77T shows us something important: biology doesn't know whether a patient has single- or multistation N2 disease.

Those at the highest risk of micrometastatic disease may also have the most to gain from our best systemic therapy upfront.

#BTGLung2026 @OncLive @BrendonStilesMD

[Eric K. Singhi, MD @lungoncdoc]

@BrendonStilesMD kicks off day 2 of #BTGLung2026.

"Unresectable" should be a multidisciplinary discussion...not a reflex.

As our systemic therapies improve, reassessment after induction may create opportunities that didn't exist at diagnosis. Are we reevaluating enough?

[David Gandara @drgandara]

Perfect @lungoncdoc this is the topic that I am speaking about ILCC later this week. Any issues, the "jury is still out" in my opinion. @gotoPER

[Eric K. Singhi, MD @lungoncdoc]

@hari_keshava @PatelOncology @OncLive 💯

[Eric K. Singhi, MD @lungoncdoc]

I've said this often... in lung cancer management, think chess, not checkers.

Dr. @PatelOncology agrees, and stresses this message here at #BTGLung2026 for our patients w/ EGFR+ lung cancer.

@OncLive

[Eric K. Singhi, MD @lungoncdoc]

Caught in real time!

[Misty Dawn Shields @drshieldsmd]

@lungoncdoc @OncLive @DrEdKim @NarjustFlorezMD It’s like watching “Inception” here with Dr. Eric Singhi tweeting live top clinical and research gaps in lung cancer care at the #BTGLung26

[Eric K. Singhi, MD @lungoncdoc]

5 biggest unanswered questions in early-stage #EGFR lung cancer?

1. Who needs chemotherapy?
2. How long should we treat?
3. Can ctDNA guide decisions?
4. Who benefits from perioperative therapy?
5. What's the best strategy at recurrence?

#BTGLung2026 @OncLive

[Lukas Jäger-Meister @OncoAdvLukas]

@NarjustFlorezMD @drshieldsmd @lungoncdoc @OncLive @COlazagasti @alissajcooper Love that SCLC leads the program!! Still so much work to do for these patients.